Who are Lenvatinib, tislelizumab, gemcitabine and cisplatin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lenvatinib-tislelizumab-gemcitabine-and-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Lenvatinib, tislelizumab, gemcitabine and cisplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lenvatinib, tislelizumab, gemcitabine and cisplatin (Lenvatinib, tislelizumab, gemcitabine and cisplatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination. Area: Oncology.

phase 3 Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination FGFR, VEGFR, RET (lenvatinib); PD-1 (tislelizumab); DNA (gemcitabine, cisplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lenvatinib, tislelizumab, gemcitabine and cisplatin (Lenvatinib, tislelizumab, gemcitabine and cisplatin) — Second Affiliated Hospital, School of Medicine, Zhejiang University. This combination uses lenvatinib to inhibit multiple receptor tyrosine kinases, tislelizumab to block PD-1 immune checkpoints, and gemcitabine/cisplatin as cytotoxic chemotherapy agents to attack cancer cells through multiple pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lenvatinib, tislelizumab, gemcitabine and cisplatin TARGET	Lenvatinib, tislelizumab, gemcitabine and cisplatin	Second Affiliated Hospital, School of Medicine, Zhejiang University	phase 3	Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination	FGFR, VEGFR, RET (lenvatinib); PD-1 (tislelizumab); DNA (gemcitabine, cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination class)

Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lenvatinib, tislelizumab, gemcitabine and cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/lenvatinib-tislelizumab-gemcitabine-and-cisplatin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab